All studies
RecruitingTherapeutic exploratory (Phase II)Interventional

(22551) A single arm, open-label, multicenter Phase 2 study of regorafenib in participants who have been treated in a previous Bayer-sponsored regorafenib study (monotherapy or combination treatment) that has reached the primary completion endpoint, or main data analysis, or has been stopped prematurely.

This Phase 2 clinical study is for adults with solid cancer tumours who took part in a previous trial using the drug regorafenib. When an earlier clinical study ends its main testing stage, patients who are benefiting from the medicine still need a way to receive it. This study provides that continued treatment. The main aim is to check the long-term safety of regorafenib. Doctors will track any side effects people experience, record how severe those side effects are, and note whether the dose needs to be reduced or paused. Taking part helps doctors learn more about the best ways to manage this treatment over time while ensuring participants can continue their cancer therapy under careful medical supervision.

At a glance

Status
Recruiting
Phase
Therapeutic exploratory (Phase II)
Sponsor
Bayer AG
Enrolment target
5
Start
19 Feb 2024

What is this study about?

Regorafenib is a targeted cancer medicine used to slow or stop the growth of certain solid tumours. When clinical trials start, they are set up to answer specific research questions over a fixed period. Once those main questions are answered, the original trial may close. However, patients who are doing well on the treatment often need to keep taking it. This study acts as a continuation study, allowing eligible patients to keep receiving regorafenib safely.

The primary focus of this study is patient safety. Long-term treatment can cause different reactions in different people, so researchers want to understand how the body handles the medicine over longer periods. They will record any unwanted symptoms or health changes, known as side effects or adverse events, and see how mild or serious they are.

Doctors will also study how often they need to adjust a person's dose. In routine cancer care, lowering a dose or taking short breaks can help keep side effects manageable while still treating the cancer. By studying these adjustments in detail, the trial helps researchers understand how to give regorafenib safely and effectively in everyday medical practice.

Key takeaways

  • This is a Phase 2 study providing continued access to the cancer medicine regorafenib.
  • It is only open to adults who were already taking regorafenib in a previous trial.
  • The primary goal is to monitor long-term safety, side effects, and dose adjustments.
  • Patients receive regular health checks, blood tests, and doctor visits.
  • Participation is voluntary, and you can stop taking part at any time.

Who may be eligible?

This study is open to adults aged 18 and over with solid tumours who have already taken part in a previous clinical trial testing regorafenib. Both men and women can join.

To be eligible, your earlier trial must have reached its planned completion stage, completed its main analysis, or ended early. This means you must already have experience taking regorafenib under medical supervision and your care team must agree that continuing the treatment remains a good option for you.

People who have never taken regorafenib in a previous qualifying study will not be able to join. Your hospital doctor will also check your current health and test results to ensure that staying on the medication is safe for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have been diagnosed with a solid tumour cancer.
  3. I was previously enrolled in a qualifying clinical trial testing regorafenib.
  4. My previous regorafenib study has reached its main endpoint or has ended.
  5. My doctor believes that continuing regorafenib is safe and appropriate for me.
Answer every question to see your result.

What does participation involve?

Taking part involves continuing your treatment with regorafenib, which is usually taken as tablets by mouth according to your doctor's instructions. You will have regular clinic visits at the hospital so your healthcare team can check your health, carry out blood tests, monitor your blood pressure, and ask how you are feeling. Doctors will record any side effects and can lower your dose or pause treatment if needed. You will stay on the study for as long as the treatment continues to help you and remains safe, though you can choose to leave the study at any time.

Potential risks and benefits

The main benefit of taking part is having continued access to regorafenib if it is helping to keep your cancer stable. However, like all cancer medicines, regorafenib can cause side effects. Common issues can include tiredness, high blood pressure, skin reactions on the hands and feet, loss of appetite, or changes in liver function. Your medical team will monitor you closely to catch and manage any problems early. Taking part is entirely voluntary, and you are free to leave the trial at any point without it affecting your standard NHS care.

Locations (2)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Spain
  • —
    Unverified
    France

Common questions

What is regorafenib?

Regorafenib is a targeted cancer treatment that works by blocking certain proteins that cancer cells need to grow and develop blood vessels.

Can I join if I have never taken regorafenib before?

No. This particular study is only for people who were already receiving regorafenib in an earlier clinical trial that has now finished.

How long will I be in this study?

You will generally stay in the study as long as your cancer remains stable, your side effects are manageable, and your doctor agrees the medicine is helping.

What happens if I get uncomfortable side effects?

Your study doctor can adjust your daily dose, pause the medication temporarily, or provide supportive medicines to help manage side effects.

Can I leave the study if I change my mind?

Yes. You have the right to withdraw from the study at any time. Your normal medical care will continue as usual.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "(22551) A single arm, open-label, multicenter Phase 2 study …" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.